Comparison of AML vs MDS and therapy-related vs de novo complex karyotype cases
| . | AML (n = 144) . | MDS (n = 155) . | P . | Therapy-related (n = 118) . | De novo (n = 81) . | P . |
|---|---|---|---|---|---|---|
| Age (median, y) | 69 (1-91) | 70 (22-91) | .7 | 71 (37-91) | 70 (1-88) | .06 |
| Gender, M:F | 181:76 | 43:18 | 65:61 | 25:10 | ||
| WHO subtype | ||||||
| AML | 144 (100%) | — | 45 (38%) | 99 (55%) | .006 | |
| MDS-SLD | — | 1 (1%) | 0 (0%) | 1 (1%) | ||
| MDS-MLD | — | 38 (25%) | 28 (24%) | 10 (6%) | ||
| MDS–RS-SLD | — | 0 (0%) | 0 (0%) | 0 (0%) | ||
| MDS–RS-MLD | — | 11 (7%) | 5 (4%) | 6 (3%) | ||
| MDS-U | — | 1 (1%) | 0 (0%) | 1 (1%) | ||
| MDS-EB1 | — | 41 (26%) | 17 (14%) | 24 (13%) | ||
| MDS-EB2 | — | 63 (41%) | 23 (19%) | 40 (22%) | ||
| Monosomal karyotype | 81 (56%) | 100 (65%) | .15 | 79 (67%) | 102 (56%) | .07 |
| Any TP53 mutation | 113 (78%) | 134 (86%) | 0.09 | 106 (90%) | 141 (78%) | .008 |
| Multihit TP53 mutation | 94 (65%) | 86 (55%) | 0.1 | 73 (62%) | 107 (59%) | .72 |
| Blood counts | ||||||
| ANC | 0.7 (0-58.7) | 1.2 (0.02-10.1) | .0004 | 1.11 (0-58.7) | 0.83 (0-25.4) | .49 |
| HGB | 8.3 (4-13.5) | 8.8 (3.8-13.7) | .001 | 8.6 (4-13.7) | 8.6 (3.8-13.7) | .91 |
| WBC | 2.8 (0.1-281) | 3.1 (0.6-36.8) | .85 | 2.8 (0.6-88) | 3.2 (0.1-281) | .16 |
| Platelets | 47 (5-464) | 55 (3-308) | .05 | 55 (3-308) | 49 (5-464) | .37 |
| PB blasts, % | 8 (0-97) | 0 (0-16) | <.0001 | 0 (0-79) | 2 (0-97) | .002 |
| BM features | ||||||
| Cellularity, % | 77.5 (20-100) | 65 (10-100) | .0007 | 72.5 (10-100) | 70 (10-100) | .06 |
| Blast, % | 50 (14-95) | 7 (0-18) | <.0001 | 12 (0-94) | 22 (0-95) | .0003 |
| . | AML (n = 144) . | MDS (n = 155) . | P . | Therapy-related (n = 118) . | De novo (n = 81) . | P . |
|---|---|---|---|---|---|---|
| Age (median, y) | 69 (1-91) | 70 (22-91) | .7 | 71 (37-91) | 70 (1-88) | .06 |
| Gender, M:F | 181:76 | 43:18 | 65:61 | 25:10 | ||
| WHO subtype | ||||||
| AML | 144 (100%) | — | 45 (38%) | 99 (55%) | .006 | |
| MDS-SLD | — | 1 (1%) | 0 (0%) | 1 (1%) | ||
| MDS-MLD | — | 38 (25%) | 28 (24%) | 10 (6%) | ||
| MDS–RS-SLD | — | 0 (0%) | 0 (0%) | 0 (0%) | ||
| MDS–RS-MLD | — | 11 (7%) | 5 (4%) | 6 (3%) | ||
| MDS-U | — | 1 (1%) | 0 (0%) | 1 (1%) | ||
| MDS-EB1 | — | 41 (26%) | 17 (14%) | 24 (13%) | ||
| MDS-EB2 | — | 63 (41%) | 23 (19%) | 40 (22%) | ||
| Monosomal karyotype | 81 (56%) | 100 (65%) | .15 | 79 (67%) | 102 (56%) | .07 |
| Any TP53 mutation | 113 (78%) | 134 (86%) | 0.09 | 106 (90%) | 141 (78%) | .008 |
| Multihit TP53 mutation | 94 (65%) | 86 (55%) | 0.1 | 73 (62%) | 107 (59%) | .72 |
| Blood counts | ||||||
| ANC | 0.7 (0-58.7) | 1.2 (0.02-10.1) | .0004 | 1.11 (0-58.7) | 0.83 (0-25.4) | .49 |
| HGB | 8.3 (4-13.5) | 8.8 (3.8-13.7) | .001 | 8.6 (4-13.7) | 8.6 (3.8-13.7) | .91 |
| WBC | 2.8 (0.1-281) | 3.1 (0.6-36.8) | .85 | 2.8 (0.6-88) | 3.2 (0.1-281) | .16 |
| Platelets | 47 (5-464) | 55 (3-308) | .05 | 55 (3-308) | 49 (5-464) | .37 |
| PB blasts, % | 8 (0-97) | 0 (0-16) | <.0001 | 0 (0-79) | 2 (0-97) | .002 |
| BM features | ||||||
| Cellularity, % | 77.5 (20-100) | 65 (10-100) | .0007 | 72.5 (10-100) | 70 (10-100) | .06 |
| Blast, % | 50 (14-95) | 7 (0-18) | <.0001 | 12 (0-94) | 22 (0-95) | .0003 |
ANC, Absolute neutrophil count; HGB, Hemoglobin; MDS-EB1, Myelodysplastic syndrome with excess blasts-1; MDS-EB2, Myelodysplastic syndrome with excess blasts-2; MDS–RS-MLD, Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia; MDS–RS-SLD, Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia; MDS-U, Myelodysplastic syndrome, unclassifiable; PB, Peripheral blood; WBC, White blood cell count.